Meta-analysis of preclinical pharmacogenomic studies to discover robust and translatable biomarkers of drug response
Smirnov, P.; Nair, S. K.; Abbas-Aghababazadeh, F.; Feizi, N.; Smith, I.; Pugh, T. J.; Haibe-Kains, B.
Show abstract
Preclinical pharmacogenomic studies provide an opportunity to discover novel biomarkers for drug response. However, pharamcogenomic studies linking gene expression profiles to drug response do not always agree on the significance or strength of biomarkers. We apply a statistical meta-analysis approach to 7 large independent pharmacogenomic studies, testing for tissue-specific gene expression markers predictive of response among cancer cell lines. We found 4,338 statistically-significant biomarkers across 8 tissue types and 34 drugs. Significant biomarkers were found to be closer than random to drug targets in a gene network built on pathway co-membership (average distance of 2 vs 2.9). However, functional relationships with the drug target did not predict reproducibility across studies. To validate these biomarkers, we utilized 10 clinical datasets, allowing 42/4338 biomarkers to be assessed for clinical translation. Of the 42 candidate biomarkers, the expression of ODC1 was found to be significantly predictive of Paclitaxel response as a neoadjuvant treatment of breast carcinoma across 2 independent clinical studies of >200 patients each. We expect that as more clinical transcriptomics data matched with response are available, our results can be used to prioritize which genes to evaluate as clinical biomarkers of drug response.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Personalized Cancer Therapy Prioritization Based on Driver Alteration Co-occurrence Patterns 97%
- Beyondcell: targeting cancer therapeutic heterogeneity in single-cell RNA-seq 95%
- Spatial transcriptomic analysis of Sonic Hedgehog Medulloblastoma identifies that the loss of heterogeneity and promotion of differentiation underlies the response to CDK4/6 inhibition 94%
Similar papers in this journal
- Dissecting tumor cell programs through group biology estimation in clinical single-cell transcriptomics 95%
- Projecting genetic associations through gene expression patterns highlights disease etiology and drug mechanisms 95%
- The DiffInvex evolutionary model for conditional somatic selection identifies chemotherapy resistance genes in 10,000 cancer genomes 95%
Similar papers in this journal
- Kinome focused CRISPR-Cas9 screens in African ancestry patient-derived breast cancer organoids identifies essential kinases and synergy of EGFR and FGFR1 inhibition. 95%
- Biomarker-guided treatment strategies for ovarian cancer identified from a heterogeneous panel of patient-derived tumor xenografts 94%
- Systematic Establishment of Robustness and Standards in Patient-Derived Xenograft Experiments and Analysis 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.